Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer - A two stage phase II clinical trial

Radiotherapy and Oncology

Volumn 102, Issue 1, 2012, Pages 10-13

  Resch, Gudrun ^a   De Vries, Alexander ^b   Öfner, Dietmar ^c   Eisterer, Wolfgang ^d   Rabl, Hans ^e   Jagoditsch, Michael ^f   Gnant, Michael ^g   Thaler, Josef ^a  

^a Klinikum Wels Grieskirchen   (Austria)

^b Hospital Feldkirch   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e Leoben Eisenerz Hospital   (Austria)

^f St Veit Hospital   (Austria)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bevacizumab; Capecitabine; Chemoradiation; Rectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANUS DISEASE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; DIARRHEA; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; FEASIBILITY STUDY; FEMALE; HAND FOOT SYNDROME; HUMAN; ILEUS; INTESTINAL BLEEDING; LEUKOPENIA; LOCALLY ADVANCED RECTUM CANCER; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; WOUND DEHISCENCE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84455191894     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.06.008     Document Type: Article

References (33)

1. D. Sebag-Montefiore, K. Bujko, and V. Valentini Rectal cancer multidisciplinary management: evidences and future landscape Radiother Oncol 92 2009 145 147
2. B. Glimelius, and J. Oliveira Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 2009 54 56
3. M. Dahlberg, B. Glimelius, and L. Pahlman Changing strategy for rectal cancer is associated with improved outcome Br J Surg 86 1999 379 384
4. J.K. McFarlane, R.P. Ryall, and R.J. Heald Mesorectal excision for rectal cancer Lancet 341 1993 457 460
5. E. Kapiteijn, C. Marijnen, and I. Nagtegaal Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer N Engl J Med 345 2001 638 646
6. Swedish rectal cancer trial: improved survival with preoperative radiotherapy in respectable rectal cancer. N Engl J Med 1997;336:980-7.
7. J. Folkesson, H. Birgisson, and L. Pahlman Swedish rectal cancer trail: long lasting benefits from radiotherapy on survival and local recurrence rate J Clin Oncol 23 2005 5644 5650
8. J.P. Gerard Radiotherapy in the conservative treatment of rectal cancer. Evidence-based medicine and opinion Radiother Oncol 74 2005 227 233
9. J. Giralt, J. Tabernero, and B. Navalpotro Pre-operative chemotherapy with UFT and leucovorin in patients with advanced rectal cancer: a phase II study Radiother Oncol 89 2009 263 269
10. G. Klautke, U. Küchenmeister, and T. Foitzik Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and optimize efficacy measured by pathologic complete response Radiother Oncol 85 2007 379 384
11. A. Debucquoy, S. Roels, and L. Goethals Double blind randomized phase II study with radiation + 5-fluorouracil ± celecoxib for resectable rectal cancer Radiother Oncol 93 2009 273 278
12. C.H. Crane, J.M. Skibber, and E.H. Birnbaum The addition of continuos infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer Int J Radiat Oncol Biol Phys 57 2003 84 89
13. K.L. Wiltshire, I.G. Ward, and C. Swallow Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival Int J Radiat Oncol Biol Phys 64 2006 709 716
14. J. Bosset, L. Collette, and G. Calais Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123
15. J. Gerard, F. Bonnetain, and T. Conroy Preoperative radiotherapy + 5 FU/folinic acid in T3-4 rectal cancer: results of the FFCD 9203 randomized trial J Clin Oncol 24 2006 4620 4625
16. D.Y. Kim, K.H. Jung, and T.H. Kim Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer Int J Radiat Oncol Biol Phys 67 2007 378 384
17. P. Das, E.H. Lin, and S. Bhatia Preoperative chemoradiotherapy with capecitabine vs protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis Int J Radiat Oncol Biol Phys 66 2006 1378 1383
18. R. Sauer, H. Becker, and W. Hohenberger Preoperative versus postoperative chemoradiatiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
19. F. Kabbinavar, H. Hurwitz, and L. Fehrenbacher Phase II randomized trial comparing bevacizumab plus fluorouracil/leucovorin with FU/LV in patients with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
20. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, flurouracil and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
21. L. Saltz, E. Diaz-Rubio, and W. Scheithauer Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
22. R. Simon Optimal two-stage designs for phase II clinical trials Controlled Clin Trials 10 1989 1 10
23. P. Hermanek, and C. Wittekind The pathologist and the residual tumor (R) classification Pathol Res Pract 190 1994 115 123
24. J.F. Bosset, L. Collette, and G. Calais Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123
25. J. Gerad, R. Bonnetain, and T. Conroy Preoperative concurrent chemoradiotherapy (CT-RT) improves local control in T3-T4 rectal cancers. Results of the FFCD 9203 randomized trial Eur J Cancer 3 2005 170
26. D. Öfner, A. DeVries, and R. Schaberl-Moser Preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with newly diagnosed, primary operable, cT3NxM0, low rectal cancer: a phase II study Strahlenther Onkol 187 2011 100 107
27. W. Eisterer, A. DeVries, and D. Öfner Neoadjuvant chemoradiation therapy with capecitabine (X) plus cetuximab (C), and external beam radiotherapy (RT) in locally advanced rectal cancer (LARC): ABCSG trial R03 J Clin Oncol 27 2009 [Abstract #4109]
28. C. Willett, D.G. Duda, and E. di Tomaso Efficacy, safety and biomarkers of neoadjuvant bevacizumab, radiation therapy and fluorouracil in rectal cancer: a multidisciplinary phase II study J Clin Oncol 27 2009 3020 3026
29. C. Willett, Y. Boucher, and D.G. Duda Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in recal cancer patients J Clin Oncol 23 2005 8136 8139
30. C.H. Crane, C. Eng, and B.W. Feig Phase II trial of neoadjuvant bevacizumab, capecitabine and radiotherapy for locally advanced rectal cancer Int J Radiat Oncol Biol Phys 76 2010 824 830
31. M.S. Gordon, K. Margolin, and M. Talpaz Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 2001 843 850
32. F. Kabbinavar, H. Hurwitz, and L. Fehrenbacher Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
33. S. Hapani, A. Sher, D. Chu, and S. Wu Increases risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis Oncology 79 2010 27 38